Search results

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

27 January 2021

Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

27 January 2021

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adult

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

17 February 2021

NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

17 February 2021

NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

17 February 2021

Evidence-based recommendations on niraparib for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

24 February 2021

Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

24 February 2021

NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

24 February 2021

Evidence-based recommendations on autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults who have

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)